From protocol to product: ventral midbrain dopaminergic neuron differentiation for the treatment of Parkinson's disease
Current cell therapy product limitations include the need for in-depth product understanding to ensure product potency, safety and purity. New technologies require development and validation to address issues of production scale-up to meet clinical need; assays are required for process control, vali...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Default Article |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/2134/10310972.v1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|